Cyclerion Therapeutics Inc (CYCN)
3.04
+0.27
(+9.75%)
USD |
NASDAQ |
Apr 25, 16:00
Cyclerion Therapeutics Free Cash Flow (Quarterly): -1.541M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.541M |
| September 30, 2023 | -6.935M |
| June 30, 2023 | -6.555M |
| March 31, 2023 | -6.214M |
| December 31, 2022 | -7.043M |
| September 30, 2022 | -9.915M |
| June 30, 2022 | -10.82M |
| March 31, 2022 | -12.84M |
| December 31, 2021 | -8.63M |
| September 30, 2021 | -7.93M |
| June 30, 2021 | -5.509M |
| March 31, 2021 | -14.46M |
| Date | Value |
|---|---|
| December 31, 2020 | -14.08M |
| September 30, 2020 | -15.06M |
| June 30, 2020 | -14.30M |
| March 31, 2020 | -30.58M |
| December 31, 2019 | -22.34M |
| September 30, 2019 | -24.46M |
| June 30, 2019 | -26.22M |
| March 31, 2019 | -36.08M |
| December 31, 2018 | -24.97M |
| September 30, 2018 | -26.46M |
| June 30, 2018 | -22.92M |
| March 31, 2018 | -26.59M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-30.58M
Minimum
Mar 2020
-1.541M
Maximum
Dec 2023
-12.92M
Average
-10.82M
Median
Jun 2022
Free Cash Flow (Quarterly) Benchmarks
| Eli Lilly and Co | -1.963B |
| iBio Inc | -4.706M |
| AbbVie Inc | 4.548B |
| Agile Therapeutics Inc | 0.172M |
| NovaBay Pharmaceuticals Inc | -0.316M |